The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1

Table 1 Summary of the colon cancer-associated DLC1-START domain mutations. TCGA colon cancer associated DLC1 START domain mutations and biological properties analyzed in this study

DLC1 mutation	Biological inhibition relative to DLC1 WT	RhoGAP activity relative to DLC1 WT	Caveolin-1 binding	PLCD1 binding	PS binding	Sensitivity to PS changes
S912L	reduced	similar	deficient	deficient	normal	normal
L930P	reduced	similar	deficient	deficient	normal	normal
R947C	reduced	similar	deficient	deficient	deficient	deficient
E966K	reduced	similar	deficient	deficient	deficient	not assayed
C1005F	reduced	similar	normal	normal	deficient	not assayed
A1017T	reduced	similar	normal	normal	deficient	not assayed
C1036S	reduced	similar	normal	normal	deficient	deficient

ISSN: 1476-4598